Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2010

View Archived Issues

Intradermal and intramuscular Fluzone are equally immunogenic

Kowa claims new erythropoietin production enhancers

Pain Therapeutics receives research grant for nervous system disorders and oncology

Lucinactant receives FDA orphan drug status in CF after encouraging phase II trial results

Preliminary phase II/III data disclosed on fosbretabulin plus chemotherapy in ATC

MLN-8237 shows promise in epithelial ovarian, fallopian tube and primary peritoneal carcinoma

Interim phase I/II data presented on dovitinib in RCC

BCN Peptides and DiverDrugs to advance DD-04107 to clinic

Amgen reviews achievements of third quarter

New indole derivatives claimed for treatment of HCV infection

Questcor Pharma's Acthar launched in U.S. for infantile spasms

New inhibitors of TNF-alpha, COX-1 and COX-2 disclosed

New progesterone receptor antagonists presented by Evestra

Bristol-Myers Squibb identifies new inhibitors of HCV NS5A

Takeda and Millennium initiate phase III TAK-700 program in prostate cancer

Adventrx Pharma submits NDA to FDA for vinorelbine

NeurogesX begins phase II NGX-1998 trial in postherpetic neuralgia

Sanofi Pasteur's ChimeriVax-Dengue vaccine enters phase III trial in Australia

Oncothyreon begins phase I/II trial of PX-866/docetaxel combination

Results reported of phase III safinamide extension study in advanced PD

Ortho-McNeil-Janssen ends collaboration with Arena Pharma for APD-597 program

Swedish Orphan Biovitrum sells back copromotion rights for Mimpara to Amgen

FDA orphan drug status for AVP-21D9 in inhalation anthrax

AEOL-10150 promotes survival in nonhuman primates exposed to radiation

Adolor receives grant from Michael J. Fox Foundation to develop dyskinesia treatments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...